Repatha and Warfarin Interaction: What Patients and Prescribers Need to Know

Why This Question Comes Up

Warfarin is one of the most interaction-prone drugs in clinical medicine, with over 200 documented drug-drug interactions catalogued in major DDI databases [1]. Patients prescribed evolocumab for familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) often already take warfarin for atrial fibrillation, mechanical heart valves, or venous thromboembolism. The concern is reasonable.

Warfarin's narrow therapeutic index means even modest changes in its metabolism can push the INR into dangerous territory, either raising bleeding risk or allowing thromboembolic events. Drugs that inhibit CYP2C9 (the primary enzyme responsible for S-warfarin clearance) are the most common culprits [2]. Amiodarone, fluconazole, and metronidazole are well-known offenders. Patients and clinicians naturally ask whether a newer injectable like Repatha carries similar risk.

The short answer: it does not. The pharmacologic profile of evolocumab makes a CYP-mediated interaction with warfarin essentially impossible, and the clinical evidence confirms this.

How Evolocumab Is Metabolized

Evolocumab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) [3]. Like all therapeutic monoclonal antibodies, it is too large (approximately 144 kDa) to serve as a substrate for cytochrome P450 enzymes or membrane transporters such as P-glycoprotein (P-gp).

Its elimination follows the same pathway as endogenous immunoglobulins: receptor-mediated endocytosis and intracellular proteolytic catabolism, primarily within the reticuloendothelial system [3]. This is a fundamentally different clearance route from small-molecule drugs. Evolocumab does not enter hepatocytes through CYP-dependent oxidative metabolism, does not compete for binding at CYP2C9 or CYP3A4 active sites, and does not induce or inhibit these enzymes.

The FDA-approved prescribing information for Repatha states: "No formal drug interaction studies have been performed" but notes that "as a monoclonal antibody, evolocumab is not expected to have pharmacokinetic interactions with other drugs" [3]. This language reflects a well-established pharmacologic principle. The European Medicines Agency's guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev.1) explicitly exempts monoclonal antibodies from standard CYP interaction studies because the biologic basis for such interactions does not exist [4].

How Warfarin Is Metabolized and Where Interactions Arise

Warfarin is administered as a racemic mixture. S-warfarin is 3 to 5 times more potent than R-warfarin and is primarily metabolized by CYP2C9, with minor contributions from CYP3A4 [2]. R-warfarin is cleared through CYP1A2, CYP2C19, and CYP3A4 [2]. Drugs that inhibit CYP2C9 produce the most clinically dangerous interactions because they raise levels of the more active S-enantiomer.

Warfarin also binds extensively to plasma albumin (approximately 99%), so displacement interactions are theoretically possible with highly protein-bound drugs [5]. Evolocumab, as a monoclonal antibody, does not bind albumin. It circulates as an intact IgG2 molecule and is not a candidate for protein-binding displacement.

Pharmacodynamic interactions with warfarin occur when co-administered drugs independently affect hemostasis. Antiplatelet agents, NSAIDs, and SSRIs are common examples. Evolocumab has no known effect on platelet function, coagulation factor synthesis, or vitamin K cycling. Its sole pharmacodynamic action is PCSK9 inhibition, which lowers LDL-cholesterol by upregulating hepatic LDL receptor recycling [3].

No mechanism exists, whether pharmacokinetic or pharmacodynamic, through which evolocumab could alter warfarin's anticoagulant effect.

Clinical Evidence from FOURIER and Other Trials

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and randomized them to evolocumab or placebo on top of statin therapy [6]. The trial population included patients receiving concomitant anticoagulants, including warfarin.

In FOURIER, the overall rate of adjudicated bleeding events did not differ between the evolocumab and placebo arms. Hemorrhagic stroke occurred in 0.2% of the evolocumab group versus 0.2% of the placebo group (P = 0.82) [6]. No subgroup analysis identified anticoagulant co-administration as a risk modifier for bleeding with evolocumab. The safety profile was consistent across all prespecified subgroups, including those on multiple cardiovascular medications.

The OSLER-1 and OSLER-2 open-label extension studies followed 4,465 patients receiving evolocumab for a median of 11.1 months with no signal of excess bleeding, including among patients on anticoagulants [7]. Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) through 2025 have not identified warfarin interaction as an emerging safety concern [8].

A population pharmacokinetic analysis published in the Journal of Clinical Pharmacology confirmed that evolocumab exposure (as measured by AUC and Cmax) was not affected by concomitant medications, including anticoagulants, and that evolocumab did not alter the pharmacokinetics of co-administered drugs in pooled trial data [9].

What DDI Databases Report

Major drug interaction databases assign different severity ratings to the evolocumab-warfarin pair:

Lexicomp classifies the combination as "no known interaction." Micromedex does not list a monograph for this pair. The Clinical Pharmacology database from Elsevier similarly reports no interaction [10]. These classifications are consistent with the absence of any mechanistic basis or clinical signal.

By contrast, the same databases flag evolocumab's companion therapy, statins, as having genuine interactions with warfarin. Rosuvastatin, for example, can modestly increase INR in warfarin-treated patients, an effect attributed to CYP2C9 competition [11]. This distinction underscores that the relevant interaction risk for patients on combination lipid-lowering and anticoagulant therapy comes from the statin, not the PCSK9 inhibitor.

Prescribers managing a patient on warfarin plus evolocumab plus a statin should focus INR surveillance on statin initiation, dose changes, or switches rather than on Repatha injections.

Monitoring Recommendations

Even though no evolocumab-warfarin interaction exists, patients on warfarin require ongoing INR monitoring regardless of what other drugs are added or removed. The American College of Chest Physicians (ACCP) recommends INR testing at least every 4 weeks for patients in a stable therapeutic range and more frequently during medication changes [12].

When starting Repatha, no additional INR checks beyond the existing schedule are necessary. The subcutaneous injection of evolocumab (140 mg every 2 weeks or 420 mg monthly) does not warrant a deviation from the patient's established anticoagulation management plan.

One practical consideration: patients who begin evolocumab and simultaneously undergo statin dose optimization may experience INR fluctuations attributable to the statin change. Clinicians should attribute any INR shift to the statin adjustment, not to evolocumab. Checking INR 5 to 7 days after a statin dose change remains standard practice [12].

Patients using direct oral anticoagulants (DOACs) such as apixaban or rivarelbaan instead of warfarin can likewise take evolocumab without concern for a drug interaction, as DOACs are cleared by CYP3A4 and P-gp pathways that monoclonal antibodies do not affect [13].

Broader Drug Interaction Profile of Evolocumab

Evolocumab's lack of CYP involvement means it carries an exceptionally clean drug interaction profile. The Repatha prescribing information does not list any contraindicated or dose-adjusted co-administrations [3].

In clinical practice, evolocumab is most commonly combined with high-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg), ezetimibe, aspirin, clopidogrel, beta-blockers, ACE inhibitors, and ARBs. None of these combinations have produced interaction signals in trials or post-marketing data [6][7].

For patients with familial hypercholesterolemia who require LDL apheresis, evolocumab can be administered on the same schedule without timing adjustments relative to apheresis sessions, though some clinicians prefer to inject Repatha at least 24 hours before a session to minimize theoretical antibody removal [3].

The only precaution noted in the Repatha label relates to hypersensitivity reactions (rash, urticaria, and rare anaphylaxis), which are class effects of monoclonal antibodies and unrelated to drug interactions [3].

Patient Counseling Points

Patients on both Repatha and warfarin benefit from clear, specific guidance. Five points worth covering at the pharmacy counter or in clinic:

1. No timing restrictions. Repatha injections can be given on any day relative to warfarin doses. There is no need to hold warfarin before or after the injection.

2. INR monitoring stays the same. Starting Repatha does not change the INR testing schedule. If the prescriber orders extra checks, it is likely due to a concurrent statin change, not the PCSK9 inhibitor.

3. Injection-site bleeding. Patients on warfarin may notice more bruising at the Repatha injection site. This is a local effect of anticoagulation, not a drug interaction. Applying gentle pressure for 30 to 60 seconds after injection can reduce bruising.

4. Report new medications. While Repatha itself does not interact with warfarin, many other drugs do. Patients should continue to report all new prescriptions, supplements, and over-the-counter medications to their anticoagulation clinic.

5. Do not stop either drug without consulting a physician. Discontinuing warfarin raises thromboembolic risk; discontinuing evolocumab causes LDL-C to return to pretreatment levels within 12 weeks [3]. Both drugs serve distinct, non-overlapping clinical purposes.

Special Populations

In elderly patients (age 75 and older), both warfarin sensitivity and cardiovascular risk are elevated. The FOURIER subgroup analysis of patients aged 75 and older (N = 2,747) showed consistent LDL-C lowering and cardiovascular benefit with no excess bleeding [14]. Evolocumab does not require renal or hepatic dose adjustment, and its interaction-free profile is particularly advantageous in older adults who typically take 5 or more medications.

Patients with moderate hepatic impairment (Child-Pugh B) may have altered warfarin metabolism due to reduced CYP activity and lower clotting factor synthesis. Evolocumab pharmacokinetics are not affected by hepatic impairment because its clearance is independent of liver enzyme function [3]. Warfarin dose titration in this population should follow standard hepatology guidance without any modification for concurrent Repatha use.

In patients with renal impairment, warfarin pharmacokinetics are largely unchanged, and evolocumab clearance is similarly unaffected [3]. No dose modification of either drug is needed based on renal function.

When to Reconsider the Combination

The question is rarely whether these two drugs interact (they do not) but whether both are still indicated. Patients on warfarin for atrial fibrillation may be candidates for DOAC conversion, which simplifies monitoring. Patients on evolocumab who achieve LDL-C goals below 55 mg/dL and have been stable for 2 or more years might discuss with their cardiologist whether continued PCSK9 inhibition is warranted based on residual risk.

The 2018 AHA/ACC cholesterol guideline recommends PCSK9 inhibitors for patients with clinical ASCVD and LDL-C of 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe therapy [15]. Warfarin indications are governed by separate risk-benefit calculations (CHA2DS2-VASc for atrial fibrillation, duration guidelines for VTE). Each drug should be evaluated on its own merits. The interaction profile between them imposes no constraints on either decision.

Repatha 140 mg prefilled syringe or autoinjector costs approximately $5,850 per year at wholesale acquisition cost (WAC) as of 2026, while warfarin remains one of the least expensive prescription drugs at roughly $48 per year for generic tablets [16]. Cost and insurance coverage are more common barriers to combination therapy than safety concerns.